

Health Canada and JTI-Macdonald Corp. meeting: Reduced Risk Products – May 3, 2019

Subject:

Reduced Risk Products

Date:

May 3, 2019

Participants:

Health Canada (HC)

- Dana Beaton
 - Director, Office of Policy and Strategic Planning, Tobacco Control Directorate (TCD) (chair)
- Denis Choinière
 - Director, Tobacco Products Regulatory Office, TPRO, TCD
- Manager, Science Division, TCD
- Science Regulatory Officer, Regulatory Division, TCD
- Senior Advisor, Director General's Office, TCD
- Acting Policy Analyst, TPRO, TCD

JTI-Macdonald Corp. (JTI)

- Dr. Ian Jones
 - Vice President, Reduced Risk Products portfolio
- Caroline Evans
 - Head of Corporate Affairs & Communications

Introduction:

A meeting was held at the request of JTI to present:

- Launch of Logic Compact in Canada;
- Science behind JTI's reduced risk products portfolio;
- Nicotine concentration and nicotine salts.

The Chair opened the meeting by doing round table introductions.

The Chair reminded participants that this meeting is subject to disclosure as per HC's [Openness and Transparency policies](#). In the interest of transparency, the department stated that it would be making a record of the meeting publicly available. The [handling of information and privacy notice](#) was mentioned and acknowledged.

HC also referred to Article 5.3 of the [World Health Organization Framework Convention on Tobacco Control](#), its international obligation to protect tobacco control policies from the vested interests of the tobacco industry. It was acknowledged by the JTI representatives.

Subjects:

Device – Logic Compact

JTI provided an overview of its closed-tank system which was

launched in Canada in early 2019. Representatives shared a sample of the device along with the company's e-liquid pods.

JTI representatives presented the voluntary warning message on the packaging. They indicated the company's desire to increase its portfolio by introducing a vaping product with various nicotine salts concentrations.

JTI representatives presented a deck outlining the prevalence of reduced risk products.

JTI representatives discussed their internal product stewardship and indicated that all individual ingredients undergo a toxicity analysis and risk assessment based on the full ingredient and material disclosures from suppliers, to the single chemical level.

JTI also presented a sales review and noted consumer demand for a product of this type.

Science on e-cigarettes and heated tobacco

JTI highlighted its product portfolio (heated, infused and e-vapor) as well as an emission analysis of smoke and vapor constituents. JTI also presented its findings on nicotine delivery for its products compared to cigarettes and a toxicology assessment for aerosols.

Nicotine concentration and nicotine salts

JTI presented information on the effect of pH on nicotine salts.

Conclusion:

The meeting was then concluded.

Documents:

- N/A